Vivekanand Jha's Publications

About Vivekanand Jha's Publications

Executive Director, The George Institute for Global Health, India
  • PHD

  • Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis

    Clinical Kidney Journal Date published:

  • The case for increased peritoneal dialysis utilization in low- and lower-middle-income countries

    Nephrology Date published:

  • Assessing Global Kidney Nutrition Care

    Clinical Journal of the American Society of Nephrology Date published:

  • Community Perception of Chronic Kidney Disease in Supebeda, Chhattisgarh

    International Journal of Current Research and Review Date published:

  • Does Femoral Intercondylar Notch Volume Differ in Anterior Cruciate Ligament-Injured Adult Patients Compared to the Uninjured?: A Meta-Analysis

    Clinics in Orthopedic Surgery Date published:

  • Prevalence of chronic kidney disease in Asia: a systematic review and analysis

    BMJ Global Health Date published:

  • Environmental change and kidney health

    Wits Journal of Clinical Medicine Date published:

  • Humoral Response to One and Two Doses of ChAdOx1-S Vaccine in Patients on Hemodialysis

    Clinical Journal of the American Society of Nephrology Date published:

  • Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis

    New England Journal of Medicine Date published:

  • Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis

    New England Journal of Medicine Date published:

  • The ASCEND-ND trial: study design and participant characteristics

    Nephrology Dialysis Transplantation Date published:

  • Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review

    BMJ Open Date published:

  • Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases Date published:

  • Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

    Intensive Care Medicine Date published:

  • Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia

    JAMA Date published:

  • The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics

    American Journal of Nephrology Date published: